このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

進行性B細胞非ホジキンリンパ腫患者におけるIKS03

2026年11月2日 更新者:Iksuda Therapeutics Ltd.

進行性B細胞非ホジキンリンパ腫(NHL)患者におけるIKS03の安全性、耐性、最大耐量、および予備的な抗腫瘍活性を決定するための第1相コホート用量漸増および拡大試験

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

調査の概要

詳細な説明

The study will consist of 2 parts: dose-escalation (Part I) and dose-expansion (Part II). The dose-escalation part (Part I) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS03 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part II) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS03 at the RP2D.

研究の種類

介入

入学 (推定)

140

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Maryland
      • Baltimore、Maryland、アメリカ、21201
        • 引きこもった
        • University of Maryland Baltimore
      • Candiolo、イタリア
        • 募集
        • Istituto Nazionale Oncologico Candiolo
        • コンタクト:
          • Umberto Vitolo, M.D.
        • 主任研究者:
          • Umberto Vitolo, M.D.
      • Milan、イタリア
        • 募集
        • Istituto Europeo di Oncologia
        • コンタクト:
          • Enrico Derenzini, M.D.
        • 主任研究者:
          • Enrico Derenzini, M.D.
      • Milan、イタリア
        • 募集
        • Istituto Europeo Clinico Humanitas
        • コンタクト:
          • Carmelo Carlo-Stella, M.D.
        • 主任研究者:
          • Carmelo Carlo-Stella, M.D.
      • Milan、イタリア
        • 募集
        • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele
        • コンタクト:
          • Andres Jose Maria Ferreri, M.D.
        • 主任研究者:
          • Andres Jose Maria Ferreri, M.D.
    • New South Wales
      • Westmead、New South Wales、オーストラリア、2145
        • 募集
        • Westmead Hospital
        • 主任研究者:
          • Amanda Johnston, MD
    • South Australia
      • Adelaide、South Australia、オーストラリア
        • 募集
        • Royal Adelaide Hospital
        • コンタクト:
          • Pratyush Giri, MBBS
        • 主任研究者:
          • Pratyush Giri, MBBS
    • Tasmania
      • Hobart、Tasmania、オーストラリア、7000
        • 募集
        • Royal Hobart Hospital
        • 主任研究者:
          • Rosemary Harrup, MD
    • Western Australia
      • Perth、Western Australia、オーストラリア
        • 募集
        • Linear Clinical Research
        • コンタクト:
          • Katharine Lewis, MD
        • 主任研究者:
          • Katharine Lewis, MD
    • Quebec
      • Montreal、Quebec、カナダ、H3T 1E2
        • 募集
        • Jewish General Hospital
        • 主任研究者:
          • Sarit Assouline, MD
        • コンタクト:
          • Sarit Assouline, MD
      • Badalona、スペイン
        • 募集
        • Institut Catala D'Oncologia
        • コンタクト:
          • Mireia Franch-Sarto, M.D.
        • 主任研究者:
          • Mireia Franch-Sarto, M.D.
      • Madrid、スペイン
        • 募集
        • Hospital Universitario Quironsalud Madrid
        • コンタクト:
          • Maria del Carmen Martinez-Chamorro, M.D.
        • 主任研究者:
          • Maria del Carmen Martinez-Chamorro, M.D.
      • Salamanca、スペイン
        • 募集
        • Hospital Clinico Universitario de Salamanca
        • コンタクト:
          • Alejandro Martin Garcia-Sancho, M.D.
        • 主任研究者:
          • Alejandro Martin Garcia-Sancho, M.D.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Males or females, ≥ 18 years of age

  2. Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible

  3. Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:

    1. Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)
    2. Follicular lymphoma (including duodenal-type follicular lymphoma)
    3. Mantle cell lymphoma
    4. B cell lymphomas not specified
  4. If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response

  5. NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy

  6. Must be in need of systemic treatment and not require immediate cytoreductive therapy

  7. Part I: measurable or non-measurable disease

  8. Part II: measurable disease according to The Revised Criteria/Lugano Classification

  9. Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy

  10. ECOG performance status 0 or 1

  11. Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period.

  12. Ability to understand and give written informed consent

Exclusion Criteria:

  1. Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding

  2. Patients documented to be CD19-negative

  3. Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement

  4. Part 2: History of another malignancy within 2 years, with the exception of:

    1. Treated, non-melanoma skin cancers
    2. Treated carcinoma in situ (e.g., breast, cervix)
    3. Controlled, superficial carcinoma of the urinary bladder
    4. T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits
    5. Papillary thyroid carcinoma Stage I treated surgically for cure
  5. Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):

    1. Hemoglobin < 8.0 g/dL
    2. Absolute neutrophil count < 1,000 per mm3
    3. Platelet count < 75,000 per mm3
  6. Any of the following laboratory abnormalities at baseline:

    1. Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome
    2. AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor
    3. Estimated GFR ≤ 60 mL/min corrected for BSA
    4. Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin
  7. Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:

    1. PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated)
    2. PTT > 1.5 × ULN; > 3× ULN if anticoagulated
  8. Any of the following laboratory abnormalities at baseline aimed at assessing renal function:

    1. Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA.
    2. Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin
  9. Patients with:

    1. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable
    2. Active uncontrolled bleeding or a known bleeding diathesis
  10. Significant cardiovascular disease or condition, including:

    1. Congestive heart failure or angina pectoris requiring therapy
    2. Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia
    3. Severe conduction disturbance (e.g., 3rd degree heart block)
    4. QTc interval ≥ 480 milliseconds
    5. Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram
    6. Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification
    7. History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months
  11. Significant liver disease, including:

    1. Non-infectious hepatitis
    2. Hepatic cirrhosis (Child-Pugh Class B and Class C)
  12. Significant pulmonary disease or condition, including:

    1. Significant symptomatic COPD, as assessed by the Investigator
    2. History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis
    3. History of pulmonary inflammatory disease, pneumonitis, ARDS
    4. History of pneumonia within 1 month
  13. Significant corneal disease or condition, including history of or current evidence of keratitis

  14. Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months

  15. Known HIV infection or AIDS

  16. Active hepatitis B virus or hepatitis C virus infection

  17. Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks

  18. Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications

  19. Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT)

  20. Known or suspected hypersensitivity to any of the excipients of formulated study drug

  21. Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks

  22. Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies)

  23. A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process

Drugs and Other Treatments to be Excluded:

  1. Receipt of:

    1. Any CD19-targeted therapy within 4 weeks
    2. Any tumor vaccine within 6 weeks (must have progressed if previously received)
  2. Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after

  3. Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks)

  4. Any other investigational treatments within 3 weeks

  5. Drugs known to impair renal function, including:

    1. NSAIDS within 3 days
    2. Aminoglycoside antibiotics, amphotericin B, etc. within 1 week
    3. Bisphosphonates within 1 month
  6. Prior solid organ transplant

  7. Allogeneic HSCT within 6 months, or:

    1. If receiving immunosuppression
    2. If with active evidence of GVHD
  8. Autologous hematopoietic stem cell transplantation (HSCT) within 3 months

  9. Radiotherapy:

    1. To target lesions within 4 weeks unless progression of the lesion has been documented
    2. To non-target lesions within 1 week
  10. Live/live-attenuated vaccines against infectious diseases within 4 weeks

  11. Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks

  12. Prophylactic use of hematopoietic growth factors within 1 week

  13. Herbal therapies and supplements within 2 weeks

  14. Strong inhibitors of cytochrome P450 within 2 weeks

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dose Escalation Cohort (Part 1)

Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

実験的:Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

実験的:Dose Expansion: Follicular Cell Lymphoma Participants

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

実験的:Dose Expansion: Mantle Cell Lymphoma Participants

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

実験的:Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])

Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recommended Phase 2 Dose (Part I)
時間枠:Up to 20 months

RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data

Up to 20 months
Objective Response Rate (Part II)
時間枠:up to 42 months

Antineoplastic effects will be assessed by Criteria for Response Assessment: The Lugano Classification (Cheson 2014)

up to 42 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Evaluation of the immunogenicity of IKS03 (Part I and II)
時間枠:Up to 42 months

Occurrence of ADA measured in serum at selected timepoints during the study

Up to 42 months
Plasma Concentrations of IKS03 (Part I and II)
時間枠:Up to 42 months

Pharmacokinetic profile will be characterized by concentrations of IKS03

Up to 42 months
Determine recommended Phase 2 dose (RP2D) (Part II)
時間枠:Up to 42 months

Based on evidence of antitumor activity, acceptable tolerability, evidence of achieving target plasma concentration

Up to 42 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Debra Wood, MD、Iksuda Therapeutics

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年9月5日

一次修了 (推定)

2027年9月1日

研究の完了 (推定)

2028年9月1日

試験登録日

最初に提出

2022年5月2日

QC基準を満たした最初の提出物

2022年5月6日

最初の投稿 (実際)

2022年5月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する